INMD News and Press, InMode Ltd. From 01/16/24

InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Revenue Between $126.0M-$126.5M InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Reven...

2024-01-15 15:49:19 ET More on Align Technology, DexCom, etc. Intuitive Surgical: Strong Pre-Announced Q4 - Time To Harvest The Gain, Initiate With 'Sell' Intuitive Surgical, Inc. (ISRG) JPMorgan Healthcare Conference Call Transcript Intuitive Surgical: Sustained Gro...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

2024-01-03 03:16:23 ET Summary InMode has a depressed valuation with a forward P/E of 8.70 in 2024. The company is facing challenges with falling revenue and EBITDA, despite being highly profitable. The weakening of Covid pent-up demand adds an interesting layer to the investm...

2024-01-02 10:00:00 ET Summary INMD continues to report robust consumable sales, with the downgraded FY2023 top-line guidance only attributed to the elevated interest rate environment. With the Fed already signaling a potential pivot in Q1'24, investors only need to be patient for...

2023-12-14 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NEW YORK, NY / ACCESSWIRE / December 7, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of InMode Ltd. ("InMode" or "the Company") (NASDAQ:INMD). Investors who purchased InMode securities are encouraged to obtain additional information and ...

2023-12-06 08:38:42 ET More on pre-market losers and stocks. NeuroSense: A Hold Ahead Of Phase 2b ALS Data NeuroSense ALS candidate meets key study goals Janover inks strategic referral partnership with La Rosa Holdings Seeking Alpha’s Quant Rating on ...

2023-12-06 07:12:09 ET Inmode ( NASDAQ: INMD ) shares plunged 11% premarket on Wednesday after the medtech firm lowered its full-year 2023 guidance citing headwinds from the current macroeconomic environment. The Yokneam, Israel-based firm sees stronger-than-expected hea...

InMode Revises Full-Year 2023 Guidance PR Newswire YOKNEAM, Israel , Dec. 6, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it is revising its full-year 2023 guidance. ...